belantamab mafodotin-blmf (Blenrep)
Jump to navigation
Jump to search
Indications
- treatment of adult patients with relapsed or refractory multiple myeloma
- at least 4 prior therapies including
- anti-CD38 monoclonal antibody
- a proteasome inhibitor
- an immunomodulatory agent
- at least 4 prior therapies including
* GSK withdraws Blenrep (belantamab mafodotin-blmf) from the US market at the request of the US Food & Drug Administration (FDA)[1]
Dosage
- 2.5 mg/kg IV infusion over ~30 minutes once every 3 weeks , 100 mg lyophilized powder in a single-dose vial for reconstitution & further dilution.
Adverse effects
- > 20%: keratopathy, decreased visual acuity, blurred vision, nausea, pyrexia, infusion-related reactions, fatigue
- > 5%: thrombocytopenia, lymphopenia, anemia, neutropenia
- > 5%: increased serum GGT, increased serum creatinine
Mechanism of action
- B-cell maturation antigen (BCMA)-directed antibody & microtubule inhibitor conjugate
Management
- whenever possible bring patients up to date on vaccinations prior to initiating biologic immunosuppressive agent[1]
More general terms
References
- ↑ 1.0 1.1 1.2 GSK. Nov 22, 2022 GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/
- ↑ Highlights of prescribing information Blenrep (belantamab mafodotin-blmf) for injection, for intravenous use https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF